Thursday, September 18, 2025

Latest

Cognetivity’s Assessment Tool To Be Deployed At KetamineOne Clinics Across North America

Cognetivity Neurosciences (CSE: CGN) will soon see its cognitive assessment tool for the early detection of changes in cognitive performance arrive in North America. The company this morning announced an agreement with KetamineOne Capital (NEO: MEDI) for the deployment of the tool at its clinics across the continent.

The tool, referred to as ICA, is to be utilized by KetamineOne as a long-term monitoring solution in patients that currently have both treatment-resistant depression as well as post-traumatic stress disorder. The tool will enable the company to measure the efficacy of treatment options utilized on the patient, enabling the refinement of outcomes.

The duo have also entered into a letter of intent, focused on collaborating on mental health assessments as well as conducting clinical trials within the KetamineOne clinic network, as Cognetivity works to further develop mental health assessment tools.

“We’re very excited about this deployment, which will see the ICA used in clinical care in North America for the very first time. This is a key step in our plans for commercial rollout across the US and Canadian healthcare markets and indeed throughout the world. It is also fantastic to see the ICA making its mark in another area of medicine beyond its core use case of enhancing dementia detection and diagnosis,” commented Cognetivity CEO Dr Sina Habibi.

The step into mental health monitoring through the cognitive assessment tool dramatically increases the total addressable market for the company. Mental health conditions are estimated to cost more than 12 billion working days per year, with the market for anxiety and depression treatments alone estimated at US$238 billion.

A timeline for the rollout of the ICA within KetamineOne clinics was not provided.

Cognetivity Neurosciences last traded at $0.76 on the CSE, while KetamineOne last traded at $1.45 on the Neo.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why $10K Gold No Longer Sounds Crazy | Dan Wilton – First Mining Gold

The Pure Silver Set Up! | Joaquin Marias – Argenta Silver Corp

Why $30,000 Gold Isn’t Crazy! | Simon Marcotte – Northern Superior

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cognetivity: Developing Tech For Early Detection Of Alzheimer’s – The Daily Dive feat Sina Habibi

For the final episode of The Deep Dive this week, we sit down with Sina...

Friday, May 14, 2021, 01:30:00 PM

Cognetivity: Echelon Raises Price Target To $1.50 After Biogen Approval

Monday was a very big day for companies who are in the business to help...

Wednesday, June 9, 2021, 11:22:00 AM

Cognetivity Neurosciences Sees Scientific Paper Outline Strong Use-Case For Integrated Cognitive Assessment Test

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has seen another publication of a...

Wednesday, July 7, 2021, 09:31:46 AM

Cognetivity Expands To Asian Market Via Pilot Program In Singapore

Cognetivity Neurosciences (CSE: CGN) continues to expand upon its global reach, this morning announcing its...

Tuesday, July 5, 2022, 08:01:43 AM

KetamineOne Sees CRO Subsidiary Apply For Controlled Substance Dealers License

KetamineOne Capital (NEO: MEDI) this morning announced that its wholly-owned subsidiary, KGK Science, has hit...

Wednesday, July 28, 2021, 08:48:51 AM